Turkey Puts Priority On Health Care, Eyes Nationally Developed Drugs
This article was originally published in PharmAsia News
Executive Summary
Turkey’s High Council of Science and Technology has thrown its weight behind a push to attract more pharmaceutical investment by declaring healthcare a priority sector of the economy. But attracting investment at home and from abroad remains a challenge as the government looks to keep its overall medical budget in check.
You may also be interested in...
Turkish Medtechs Up In Arms Over Partial Write-Off Of $2Bn+ Hospital Debt
Unpaid hospital debts have been hitting the Turkish medical sector for some time, but a government plan to repay less than the full amount owed has angered industry.
Turkey’s $2.6Bn Hospital Medtech Debts Create Problems On Top Of COVID-19
Turkey’s efforts to control rising rates of COVID-19 are compromising the ability of hospitals to pay their debts to medtech and pharmaceutical companies. The government has devised a payments plan, but there is catch.
COVID-19 Pushes Ongoing Concerns of Turkish Medtech Industry Down The Agenda
The Turkish medtech industry’s ongoing hospital payments problems appeared likely to come back onto the government’s agenda, with the national economy recovering somewhat in late 2019. But COVID-19 dashed those hopes.
Need a specific report? 1000+ reports available
Buy Reports